{"gene":"VHL","run_date":"2026-06-11T09:02:06","timeline":{"discoveries":[{"year":2001,"finding":"pVHL binds to a short HIF-derived peptide only when a conserved proline residue is hydroxylated; proline hydroxylation requires molecular oxygen and Fe2+, establishing pVHL as the oxygen-sensitive substrate-recognition component of an E3 ubiquitin ligase that targets HIFα for proteasomal destruction.","method":"Peptide-binding assay with hydroxylated vs. non-hydroxylated HIF-derived peptides; functional ubiquitination assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct biochemical binding assay with hydroxylated peptides, reconstituted the oxygen-dependent recognition mechanism, widely replicated across multiple labs","pmids":["11292862"],"is_preprint":false},{"year":2009,"finding":"pVHL localizes to the mitotic spindle in mammalian cells; its functional inactivation causes spindle misorientation via unstable astral microtubules, reduced Mad2 levels leading to spindle checkpoint weakening, and chromosomal instability. Restoration of wild-type pVHL (but not microtubule-stabilization-defective VHL disease mutants) rescued spindle misorientation.","method":"Immunofluorescence localization to mitotic spindle; VHL re-expression rescue experiments; Mad2 knockdown/overexpression epistasis; analysis of VHL disease mutants; aneuploidy scoring in human renal cancer","journal":"Nature Cell Biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (localization, rescue with WT vs. mutant pVHL, genetic epistasis with Mad2), corroborated in human tumor tissue","pmids":["19620968"],"is_preprint":false},{"year":2005,"finding":"VHL-interacting deubiquitinating enzyme 2 (VDU2), but not VDU1, interacts with HIF-1α and specifically deubiquitinates and stabilizes it, counteracting pVHL-mediated ubiquitination, thereby increasing HIF-1α target gene expression (e.g., VEGF).","method":"Co-immunoprecipitation (VDU2–HIF-1α interaction); in vivo deubiquitination assay; reporter gene assays for VEGF expression","journal":"EMBO Reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and functional deubiquitination assay in single lab, two orthogonal methods","pmids":["15776016"],"is_preprint":false},{"year":2006,"finding":"pVHL directly associates with and positively regulates tumor suppressor p53 by inhibiting Mdm2-mediated ubiquitination of p53 and by recruiting p53-modifying enzymes; VHL-deleted RCC cells show attenuated DNA-damage response that is restored by pVHL re-expression.","method":"Co-immunoprecipitation (pVHL–p53 interaction); ubiquitination assays; cell-cycle and apoptosis assays in VHL-null vs. pVHL-restored RCC cells","journal":"Cell Cycle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination assay, and functional rescue in single lab with multiple orthogonal readouts","pmids":["16969113"],"is_preprint":false},{"year":2006,"finding":"VHL inactivation suppresses E-cadherin expression through HIF activation; HIF activation is both necessary and sufficient to suppress E-cadherin in renal cancer cells, and VHL re-expression in VHL-defective RCC lines restores E-cadherin.","method":"VHL re-expression in RCC4 and RCC10 cell lines; HIF activation experiments; E-cadherin expression assays by western blot/immunostaining","journal":"Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional rescue with VHL re-expression and epistasis showing HIF requirement, single lab with multiple methods","pmids":["16585181"],"is_preprint":false},{"year":2010,"finding":"VHL inactivation induces HEF1/NEDD9 and Aurora kinase A via HIF-1 and HIF-2 stabilization; Aurora kinase A promotes primary cilium regression via HDAC-dependent tubulin depolymerization, and HEF1 at the centrosome enhances this effect. Suppression of this pathway improved primary cilium formation and reduced cell motility in VHL-defective cells.","method":"Gene expression analysis; knockdown/overexpression experiments in VHL-defective renal cancer cells; cilium formation assays; cell motility assays","journal":"Journal of the American Society of Nephrology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function experiments with defined phenotypic readouts (ciliation, motility), pathway placement via HIF epistasis, single lab","pmids":["20864688"],"is_preprint":false},{"year":2013,"finding":"SOCS1 promotes K63-ubiquitylation of VHL in response to DNA double-strand breaks (DSBs), causing nuclear redistribution of VHL; loss of VHL or VHL mutations that compromise K63-ubiquitylation attenuates homologous recombination repair and increases persistence of DSBs.","method":"Co-immunoprecipitation; ubiquitination assays (K63-specific); DNA damage assays (γH2AX foci, comet assay); nuclear fractionation; HR repair assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical methods (Co-IP, K63 ubiquitination, HR assay), functional link to DNA repair established, single lab","pmids":["23455319"],"is_preprint":false},{"year":2010,"finding":"VHL undergoes ubiquitylation at lysine residues 171 and 196, which destabilizes VHL and promotes cytoplasmic localization; SUMOylation at K171 (mediated by PIASy) blocks ubiquitylation, increases VHL stability, and promotes nuclear redistribution. Mutation of K171 and K196 to arginine abrogates VHL's inhibitory function on HIFα transcriptional activity.","method":"VHL-SUMO1/ubiquitin fusion proteins; subcellular fractionation; reporter assays for HIFα transcriptional activity; tube formation assay","journal":"PLoS ONE","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis with functional readouts (HIFα activity, tube formation), localization data, single lab","pmids":["20844582"],"is_preprint":false},{"year":2013,"finding":"Adenoviral Gam1 protein, via its BC-box domain competing with VHL for Elongin B/C binding, induces VHL proteasomal degradation through a CRL-dependent mechanism, leading to HIF-1α stabilization; cellular BC-box proteins and SOCS domain-containing viral proteins can similarly drive VHL degradation.","method":"Co-immunoprecipitation; proteasome inhibitor rescue experiments; HIF-1α reporter assays; domain mapping with BC-box mutants","journal":"PNAS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, domain mapping, functional reporter assays, single lab with multiple orthogonal methods","pmids":["24145437"],"is_preprint":false},{"year":2014,"finding":"DJ-1 (PARK7) interacts with VHL protein and negatively regulates VHL's ubiquitination activity toward HIF-1α by inhibiting the HIF–VHL interaction; DJ-1 deficiency leads to lowered HIF-1α levels under hypoxia and oxidative stress, and HIF-1α accumulation rescues DJ-1-deficient neurons from toxicity.","method":"Co-immunoprecipitation (DJ-1–VHL); HIF-1α ubiquitination and stability assays; HIF-1α accumulation assays in knockout models; neuroprotection assays","journal":"Journal of Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and functional ubiquitination assays, single lab, multiple methods","pmids":["24899725"],"is_preprint":false},{"year":2016,"finding":"ID2 binds to the VHL ubiquitin ligase complex, displaces VHL-associated Cullin 2, and impairs HIF2α ubiquitylation and degradation. DYRK1A/B phosphorylation of ID2 at Thr27 (stimulated by PHD1/EGLN2 in normoxia) blocks the ID2–VHL interaction, preserving HIF2α ubiquitylation.","method":"Co-immunoprecipitation (ID2–VHL complex); ubiquitination assays for HIF2α; kinase assays (DYRK1A/B phosphorylation of ID2); phospho-site mutagenesis; glioma xenograft models","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical reconstitution of the ID2-VHL interaction, site-specific mutagenesis of Thr27, kinase assays, and in vivo xenograft validation in one rigorous study","pmids":["26735018"],"is_preprint":false},{"year":2013,"finding":"Missense mutant pVHL retains E3 ligase function (including HIFα degradation) but is unstable due to misfolding and imbalance of chaperonin binding; HDAC inhibitors stabilize missense pVHL by modulating the HDAC-Hsp90 chaperone axis, restoring activity comparable to wild-type protein.","method":"In vitro E3 ligase assays; chaperone interaction studies; HDACI treatment with protein stability measurements; xenograft tumor growth assays","journal":"Cell Reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro E3 ligase assay combined with chaperone interaction studies and in vivo rescue, single lab","pmids":["23318261"],"is_preprint":false},{"year":2014,"finding":"RSUME physically interacts with pVHL, sumoylates it, and negatively regulates assembly of the pVHL–Elongin–Cullin (ECV) complex, thereby inhibiting HIF-1α and HIF-2α ubiquitination and degradation; RSUME is required for the loss-of-function of type 2 pVHL mutants.","method":"Co-immunoprecipitation (RSUME–pVHL); SUMOylation assays; ECV assembly assays; HIF ubiquitination assays; HIF stability reporter; xenograft assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, SUMOylation assay, ubiquitination assay, and in vivo xenograft, single lab, multiple orthogonal methods","pmids":["25500545"],"is_preprint":false},{"year":2017,"finding":"Daam2 associates with VHL and facilitates its ubiquitination and proteasomal degradation, providing a non-mutational mechanism of VHL suppression in glioma; inverse correlation between Daam2 and VHL expression was found across cancers including glioma.","method":"Co-immunoprecipitation (Daam2–VHL); ubiquitination assays; VHL protein stability measurements; tumor growth assays","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination assay, functional tumor growth assay, single lab","pmids":["29053101"],"is_preprint":false},{"year":2017,"finding":"VHL loss stabilizes HIF2α–HIF1β heterodimer binding at enhancers, subsequently recruiting histone acetyltransferase p300 to acquire active enhancer marks (H3K27ac, H3K4me1) near ccRCC hallmark genes, driving enhancer/superenhancer deregulation without overtly affecting preexisting promoter–enhancer interactions.","method":"ChIP-seq (H3K27ac, H3K4me1, HIF2α, p300); chromatin profiling in 10 primary tumor/normal pairs and 9 cell lines; VHL loss-of-function genetic models","journal":"Cancer Discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq across large sample set with multiple histone marks and transcription factor binding, mechanistic link to p300 recruitment established, single lab","pmids":["28893800"],"is_preprint":false},{"year":2018,"finding":"pVHL re-expression in pVHL-defective renal carcinoma cells elevates CHCHD4 (a mitochondrial intermembrane space protein import component) and respiratory chain subunits (NDUFB10, mtCO-2, COX IV), enhancing oxygen consumption rate; this effect is distinct from HIF-α regulation and is also recapitulated by HIF-2α knockdown.","method":"VHL re-expression in 786O and RCC10 cells; oxygen consumption rate measurements; western blot for respiratory chain subunits; metabolic profiling; mitochondrial morphology analysis","journal":"Frontiers in Oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional rescue with VHL re-expression and HIF-2α knockdown, multiple metabolic readouts, single lab","pmids":["30338240"],"is_preprint":false},{"year":2019,"finding":"TBK1 hydroxylation on Proline 48 triggers VHL binding (as well as phosphatase PPM1B binding), leading to decreased TBK1 phosphorylation; in the absence of VHL, TBK1 is hyperactivated and phosphorylates p62/SQSTM1 on Ser366, which is essential for p62 stability and kidney cancer cell proliferation.","method":"Co-immunoprecipitation (VHL–TBK1); hydroxylation assays; phosphorylation assays; VHL loss-of-function studies; xenograft models","journal":"Cancer Discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, hydroxylation and phosphorylation assays, in vivo xenograft, single lab with multiple orthogonal methods","pmids":["31810986"],"is_preprint":false},{"year":2021,"finding":"VHL interacts with RAPTOR (regulatory-associated protein of mTOR) and increases RAPTOR degradation by ubiquitination, thereby inhibiting mTORC1 signaling; loss of vhl-1 in C. elegans increases mTORC1 activity, supporting evolutionary conservation of this mechanism.","method":"Co-immunoprecipitation (VHL–RAPTOR); ubiquitination assays; mTORC1 activity assays; C. elegans vhl-1 loss-of-function genetics","journal":"Scientific Reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination assay, functional mTORC1 readout, cross-species genetic validation, single lab","pmids":["34290272"],"is_preprint":false},{"year":2020,"finding":"The E3 ligase VHL interacts with Daam2, and their mutual antagonism regulates oligodendrocyte differentiation during development; the E3 ubiquitin ligase Nedd4 stabilizes VHL via K63-linked ubiquitination. This Daam2-VHL-Nedd4 axis is required for developmental myelination and remyelination after white matter injury.","method":"Proteomic analysis of Daam2–VHL complex; co-immunoprecipitation; conditional knockout mouse models; K63 ubiquitination assays; demyelination mouse models; human MS lesion analysis","journal":"Genes & Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — proteomic complex analysis, Co-IP, K63 ubiquitination assay, conditional KO mice, and human disease tissue corroboration across multiple orthogonal methods","pmids":["32792353"],"is_preprint":false},{"year":2024,"finding":"VHL suppresses autophagy by directly binding to Beclin1 after PHD1-mediated hydroxylation of Beclin1 on Pro54; this binding inhibits the Beclin1–VPS34 complex association with ATG14L, blocking autophagy initiation. Non-hydroxylatable Beclin1-P54A abrogates VHL-mediated autophagy inhibition.","method":"Co-immunoprecipitation (VHL–Beclin1); PHD1 hydroxylation assays; Pro54 site-directed mutagenesis; VPS34 complex pull-down; autophagy flux assays; xenograft tumor models","journal":"The EMBO Journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct binding assay, hydroxylation assay, site-directed mutagenesis of the critical proline, and complex assembly assay in one rigorous study","pmids":["38360997"],"is_preprint":false},{"year":2022,"finding":"VHL acts as a bona fide E3 ligase for STING in renal cell carcinoma; VHL-recruiting STING PROTACs further promote VHL-dependent STING degradation, and locking STING on the endoplasmic reticulum via mutagenesis blocks its translocation to the proteasome and prevents degradation.","method":"PROTAC-mediated degradation assays; STING localization mutagenesis (ER retention); co-immunoprecipitation; downstream innate immune signaling assays","journal":"Cellular and Molecular Life Sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, degradation assay, mutagenesis-based localization rescue, single lab with multiple orthogonal methods","pmids":["37183204"],"is_preprint":false},{"year":2024,"finding":"Lactylation of HIF-1α at K644 (mouse) or K12 (human/pig) reduces K48-linked ubiquitination and proteasomal degradation by sterically hindering VHL binding without affecting prolyl hydroxylation of HIF-1α; lactylated HIF-1α retains increased transcriptional activity (elevated VEGFA, GLUT1 promoter occupancy).","method":"Mass spectrometry identification of lactylation sites; site-directed mutagenesis; K48 ubiquitination assays; VHL co-immunoprecipitation with lactylated vs. non-lactylated HIF-1α; structural modeling; chromatin immunoprecipitation","journal":"Cell Communication and Signaling","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — mutagenesis, MS-based modification identification, ubiquitination assays, and VHL binding assays in single lab with multiple orthogonal methods","pmids":["40760493"],"is_preprint":false},{"year":2024,"finding":"UBE2S promotes K11-linkage polyubiquitination of VHL at lysine residues 171 and 196 independently of E3 ligase activity, mediating VHL proteasomal degradation and indirectly stabilizing HIF-1α to promote glycolysis in hepatocellular carcinoma.","method":"Co-immunoprecipitation; ubiquitination assays (K11-specific); VHL stability measurements; glycolysis assays; HIF-1α protein level analysis","journal":"Clinical and Molecular Hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, specific K11 ubiquitination assay, functional glycolysis and HIF-1α stability readouts, single lab","pmids":["38915206"],"is_preprint":false},{"year":2022,"finding":"iASPP directly binds to the β domain of VHL (the region involved in HIF-1α binding), blocking VHL's binding to and degradation of HIF-1α under normoxia, thereby promoting angiogenesis and glycolysis in VHL wild-type tumors.","method":"Co-immunoprecipitation (iASPP–VHL); domain mapping (β domain); HIF-1α ubiquitination and stability assays; in vitro binding competition assays; tumor xenograft models","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping, ubiquitination competition assay, in vivo xenograft, single lab","pmids":["35169254"],"is_preprint":false},{"year":2021,"finding":"VHL inhibitor VH298 stabilizes VHL protein isoforms (without changing transcript levels), which in turn reduces HIF-1α protein levels, demonstrating a negative feedback mechanism where VHL inhibitor-mediated blocking of the VHL–HIF-α interaction paradoxically increases VHL protein abundance.","method":"Quantitative mass spectrometry proteomics; VHL stability assays (cycloheximide chase); transcript level analysis; HIF-1α western blot after VH298 treatment","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative MS proteomics combined with functional protein stability assays, single lab, two orthogonal methods","pmids":["34174286"],"is_preprint":false},{"year":2013,"finding":"VHL loss alone causes DNA replication stress and DNA damage accumulation in renal epithelial cells, constraining proliferation; concomitant loss of PBRM1 rescues VHL-induced replication stress and allows proliferation. Combined deletion of Vhl and Pbrm1 in mouse kidney is sufficient for fully-penetrant, multifocal carcinoma development.","method":"DNA damage markers (γH2AX); replication stress assays; conditional mouse knockout (Vhl, Pbrm1, or both); histopathological analysis of kidney tumors","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in mouse KO models with defined molecular readout (replication stress), corroborated in human tumor context","pmids":["29229903"],"is_preprint":false},{"year":2013,"finding":"Tumor suppressor VHL is required for proper spindle orientation and mitotic checkpoint fidelity in vivo: Vhl-deficient kidney cells after ischemic injury demonstrate spindle misorientation and aneuploidy (lagging chromosomes, indicating checkpoint impairment) within days, followed by ccRCC precursor lesion development at 4 months.","method":"Ischemic kidney injury model; conditional Vhl knockout mice; immunofluorescence for spindle orientation; FISH for aneuploidy; histopathological analysis","journal":"Cancer Research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo conditional knockout with defined mitotic phenotypes corroborating earlier in vitro findings, multiple orthogonal readouts","pmids":["24362914"],"is_preprint":false},{"year":2024,"finding":"Saturation genome editing of VHL's entire coding sequence quantified functional effects of 2,268 VHL single-nucleotide variants; function scores identified a core set of pathogenic alleles driving ccRCC, distinguished from pheochromocytoma-associated alleles, and revealed that some variants impact VHL function through mRNA dosage effects rather than protein dysfunction.","method":"Saturation genome editing (base editing + selection); mRNA quantification; comparison across isogenic cell lines; functional score calculation","journal":"Nature Genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — saturation genome editing with functional selection, mRNA dosage measurement, and isogenic cell line comparisons provide comprehensive mechanistic variant map","pmids":["38969834"],"is_preprint":false},{"year":2025,"finding":"A small molecule binds the HIF1α-binding pocket on pVHL and functions as a molecular glue degrader, recruiting the neosubstrate cysteine dioxygenase 1 (CDO1) into the VHL–Cullin–RING E3 ligase complex for selective ubiquitin-dependent degradation; X-ray crystal structure of the ternary VHL–CDO1–degrader complex was solved.","method":"Protein array screening; mutagenesis; protein–protein docking + molecular dynamics; X-ray crystallography of ternary complex; cellular degradation assays","journal":"Nature Chemical Biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — X-ray crystal structure of ternary complex, mutagenesis validation, and cellular degradation assay in one study","pmids":["40555806"],"is_preprint":false}],"current_model":"pVHL is the substrate-recognition subunit of a Cullin2–RING E3 ubiquitin ligase complex (CRL2VHL) that binds oxygen-dependently prolyl-hydroxylated HIFα subunits (and additional substrates including RAPTOR, Beclin1-Pro54-OH, TBK1-Pro48-OH, STING, and CDO1) to direct their K48-linked ubiquitination and proteasomal degradation; pVHL's interaction with HIFα can be blocked by lactylation of HIF-1α, by competing proteins (ID2, iASPP, DJ-1, RSUME), or by competitor E2s (UBE2S-mediated K11 ubiquitination of VHL itself), while pVHL also performs HIF-independent functions including stabilizing the mitotic spindle and Mad2 to ensure chromosomal fidelity, facilitating DNA double-strand break repair via SOCS1-mediated K63-ubiquitylation-driven nuclear redistribution, regulating CHCHD4-dependent mitochondrial function, and suppressing autophagy through direct binding to hydroxylated Beclin1."},"narrative":{"mechanistic_narrative":"pVHL is the oxygen-sensitive substrate-recognition subunit of a Cullin2–Elongin B/C–RING E3 ubiquitin ligase that couples oxygen and metabolic status to targeted protein degradation [PMID:11292862, PMID:24145437]. Its canonical role is to bind HIFα only when a conserved proline is hydroxylated in an O2- and Fe2+-dependent manner, directing HIFα for proteasomal destruction; loss of this recognition drives constitutive HIF activity that remodels enhancer landscapes via HIF2α–HIF1β/p300 recruitment, suppresses E-cadherin, and induces a HEF1/Aurora kinase A axis promoting cilium loss [PMID:11292862, PMID:28893800, PMID:16585181, PMID:20864688]. Substrate scope extends beyond HIFα to additional proline-hydroxylated and other targets, including TBK1-Pro48-OH (restraining p62/SQSTM1 phosphorylation), Beclin1-Pro54-OH (whose binding blocks VPS34–ATG14L assembly to suppress autophagy initiation), RAPTOR (inhibiting mTORC1, conserved in C. elegans), and STING [PMID:31810986, PMID:38360997, PMID:34290272, PMID:37183204]. HIFα recognition is governed by an extensive regulatory layer: deubiquitination by VDU2, competing binders that occlude the substrate interface (ID2 displacing Cullin2, iASPP binding the β domain, DJ-1, RSUME), and HIF-1α lactylation that sterically blocks VHL contact [PMID:15776016, PMID:26735018, PMID:35169254, PMID:24899725, PMID:25500545, PMID:40760493]. pVHL abundance and localization are themselves controlled by post-translational modification—SUMOylation at K171 stabilizes and nuclearizes it while ubiquitylation at K171/K196 (including K11 linkages added by UBE2S and degradation driven by Daam2 or viral BC-box proteins) destabilizes it [PMID:20844582, PMID:38915206, PMID:29053101, PMID:24145437]. pVHL also performs HIF-independent functions: it localizes to the mitotic spindle to maintain spindle orientation, Mad2-dependent checkpoint fidelity, and chromosomal stability [PMID:19620968, PMID:24362914]; undergoes SOCS1-driven K63-ubiquitylation and nuclear redistribution to support homologous recombination repair [PMID:23455319]; and elevates CHCHD4 and respiratory chain subunits to sustain mitochondrial respiration [PMID:30338240]. In renal epithelium, VHL loss causes replication stress whose rescue by concomitant PBRM1 loss yields fully penetrant clear-cell renal carcinoma, and saturation editing of the coding sequence has resolved pathogenic alleles—some acting through mRNA dosage rather than protein dysfunction [PMID:29229903, PMID:38969834]. The HIFα-binding pocket is structurally tractable and exploitable for molecular-glue degraders that recruit neosubstrates such as CDO1 [PMID:40555806].","teleology":[{"year":2001,"claim":"Established how pVHL achieves oxygen-sensitive substrate selection, answering how cells couple O2 availability to HIFα degradation.","evidence":"Peptide-binding and ubiquitination assays comparing hydroxylated vs. non-hydroxylated HIF peptides","pmids":["11292862"],"confidence":"High","gaps":["Did not enumerate non-HIF substrates","Structural basis of the ligase assembly not resolved here"]},{"year":2009,"claim":"Revealed a HIF-independent role for pVHL in mitosis, addressing how VHL loss promotes chromosomal instability beyond hypoxia signaling.","evidence":"Spindle immunofluorescence, WT vs. disease-mutant rescue, and Mad2 epistasis in mammalian cells","pmids":["19620968"],"confidence":"High","gaps":["Molecular mechanism of spindle/microtubule stabilization by pVHL undefined","How Mad2 levels are controlled by pVHL not established"]},{"year":2013,"claim":"Confirmed in vivo that VHL maintains spindle orientation and checkpoint fidelity and that its loss seeds renal carcinoma precursors, extending the in vitro mitotic findings to tissue.","evidence":"Conditional Vhl-knockout mice with ischemic injury, spindle/FISH and histopathology readouts","pmids":["24362914"],"confidence":"High","gaps":["Causal link between aneuploidy and tumor initiation not isolated","Does not define the molecular spindle substrate"]},{"year":2013,"claim":"Defined a regulated nuclear function of VHL in DNA repair, showing how DNA breaks redirect VHL to support homologous recombination.","evidence":"SOCS1-mediated K63-ubiquitylation, nuclear fractionation, and HR repair assays","pmids":["23455319"],"confidence":"Medium","gaps":["Nuclear substrate(s) of redistributed VHL unidentified","Single-lab finding"]},{"year":2013,"claim":"Showed VHL loss imposes replication stress that requires a second hit to permit tumor growth, explaining the genetic cooperation underlying ccRCC.","evidence":"γH2AX/replication-stress assays and combined Vhl/Pbrm1 conditional mouse knockouts","pmids":["29229903"],"confidence":"High","gaps":["Mechanism linking VHL loss to replication stress not fully resolved","Whether stress is HIF-dependent unclear"]},{"year":2006,"claim":"Connected VHL loss to epithelial dedifferentiation by demonstrating HIF-mediated E-cadherin suppression.","evidence":"VHL re-expression in RCC lines with HIF epistasis and E-cadherin readouts","pmids":["16585181"],"confidence":"Medium","gaps":["Direct HIF target mediating repression not pinned down","Single-lab finding"]},{"year":2005,"claim":"Identified deubiquitination as a counter-regulatory mechanism opposing pVHL, showing HIF-1α stability is set by a ubiquitination/deubiquitination balance.","evidence":"VDU2–HIF-1α Co-IP, in vivo deubiquitination, and VEGF reporter assays","pmids":["15776016"],"confidence":"Medium","gaps":["No reconstitution of the opposing enzymatic cycle","Single-lab finding"]},{"year":2010,"claim":"Established post-translational control of pVHL itself, showing SUMOylation vs. ubiquitylation at K171/K196 dictate VHL stability and localization.","evidence":"SUMO/ubiquitin fusion constructs, fractionation, and HIFα reporter assays","pmids":["20844582"],"confidence":"Medium","gaps":["Physiological triggers of K171 SUMOylation unclear","Single-lab finding"]},{"year":2010,"claim":"Defined how VHL loss drives cilium loss and motility through a HIF-induced Aurora A/HEF1 axis.","evidence":"Knockdown/overexpression in VHL-defective cells with ciliation and motility assays","pmids":["20864688"],"confidence":"Medium","gaps":["Relative HIF-1 vs HIF-2 contribution not separated","Single-lab finding"]},{"year":2013,"claim":"Distinguished folding instability from catalytic loss for missense pVHL, showing chaperone-targeting drugs can restore mutant function.","evidence":"In vitro E3 ligase assays, chaperone-interaction studies, and HDAC-inhibitor rescue with xenografts","pmids":["23318261"],"confidence":"Medium","gaps":["Generality across the missense mutant spectrum untested","Single-lab finding"]},{"year":2013,"claim":"Showed viral BC-box proteins hijack the Elongin B/C interface to degrade VHL, defining a competition-based route to HIF stabilization.","evidence":"Co-IP, proteasome rescue, and BC-box domain mapping with HIF reporters","pmids":["24145437"],"confidence":"Medium","gaps":["Endogenous BC-box competitors not comprehensively mapped","Single-lab finding"]},{"year":2014,"claim":"Identified DJ-1 as a binder that blocks the HIF–VHL interaction, linking VHL regulation to oxidative-stress neuroprotection.","evidence":"DJ-1–VHL Co-IP, HIF-1α ubiquitination/stability, and neuroprotection assays","pmids":["24899725"],"confidence":"Medium","gaps":["Binding interface on VHL not mapped","Single-lab finding"]},{"year":2014,"claim":"Established RSUME as a SUMO-dependent inhibitor of ECV complex assembly required for type-2 mutant loss-of-function.","evidence":"Co-IP, SUMOylation and ECV assembly assays, HIF ubiquitination, and xenografts","pmids":["25500545"],"confidence":"Medium","gaps":["Which SUMO sites mediate the effect not fully defined","Single-lab finding"]},{"year":2016,"claim":"Defined a phospho-regulated competitor (ID2) that displaces Cullin2 from VHL, showing kinase signaling tunes HIF2α degradation.","evidence":"ID2–VHL Co-IP, HIF2α ubiquitination, DYRK1A/B kinase assays, Thr27 mutagenesis, and glioma xenografts","pmids":["26735018"],"confidence":"High","gaps":["Selectivity for HIF2α over HIF1α not fully explained","In vivo prevalence of ID2 competition across tumors unknown"]},{"year":2017,"claim":"Showed VHL loss reprograms the enhancer landscape via stabilized HIF2α–HIF1β and p300 recruitment, linking VHL to chromatin-level gene deregulation in ccRCC.","evidence":"ChIP-seq for histone marks, HIF2α, and p300 across primary tumors and cell lines","pmids":["28893800"],"confidence":"Medium","gaps":["Causal contribution of individual enhancers to tumorigenesis untested","Single-lab finding"]},{"year":2017,"claim":"Identified Daam2 as a non-mutational driver of VHL degradation in glioma.","evidence":"Daam2–VHL Co-IP, ubiquitination, stability, and tumor growth assays","pmids":["29053101"],"confidence":"Medium","gaps":["E3 ligase mediating Daam2-driven VHL ubiquitination not defined here","Single-lab finding"]},{"year":2018,"claim":"Defined a HIF-independent role for pVHL in sustaining mitochondrial respiration via CHCHD4.","evidence":"VHL re-expression and HIF-2α knockdown with OCR and respiratory-subunit measurements","pmids":["30338240"],"confidence":"Medium","gaps":["Mechanism by which pVHL elevates CHCHD4 unresolved","Single-lab finding"]},{"year":2019,"claim":"Extended VHL substrate logic to TBK1 via Pro48 hydroxylation, showing VHL loss hyperactivates TBK1 to stabilize p62 and drive proliferation.","evidence":"VHL–TBK1 Co-IP, hydroxylation/phosphorylation assays, and xenografts","pmids":["31810986"],"confidence":"Medium","gaps":["Whether TBK1 is ubiquitinated/degraded by VHL or only sequestered unclear","Single-lab finding"]},{"year":2020,"claim":"Placed VHL in a developmental Daam2–VHL–Nedd4 axis controlling oligodendrocyte differentiation and myelination, with Nedd4 stabilizing VHL via K63 ubiquitination.","evidence":"Proteomics, Co-IP, conditional KO mice, K63 ubiquitination assays, and human MS lesion analysis","pmids":["32792353"],"confidence":"High","gaps":["Downstream VHL substrate in oligodendrocytes not defined","How the axis integrates with HIF signaling unclear"]},{"year":2021,"claim":"Identified RAPTOR as a VHL substrate, linking VHL to mTORC1 restraint with cross-species conservation.","evidence":"VHL–RAPTOR Co-IP, ubiquitination, mTORC1 activity assays, and C. elegans vhl-1 genetics","pmids":["34290272"],"confidence":"Medium","gaps":["Whether RAPTOR recognition requires hydroxylation not established","Single-lab finding"]},{"year":2021,"claim":"Revealed a negative feedback in which VHL–HIFα interface inhibitors paradoxically stabilize VHL protein.","evidence":"Quantitative MS proteomics and cycloheximide-chase stability assays after VH298 treatment","pmids":["34174286"],"confidence":"Medium","gaps":["Mechanism coupling substrate engagement to VHL turnover not resolved","Single-lab finding"]},{"year":2022,"claim":"Established STING as a VHL E3 substrate and demonstrated VHL-recruiting PROTAC degradation depending on STING trafficking.","evidence":"PROTAC degradation, ER-retention mutagenesis, Co-IP, and innate immune signaling assays","pmids":["37183204"],"confidence":"Medium","gaps":["Whether STING recognition is hydroxylation-dependent not defined","Single-lab finding"]},{"year":2022,"claim":"Identified iASPP as a β-domain competitor that blocks HIF-1α degradation even in VHL-wild-type tumors.","evidence":"iASPP–VHL Co-IP, β-domain mapping, ubiquitination competition, and xenografts","pmids":["35169254"],"confidence":"Medium","gaps":["Regulation of iASPP–VHL binding in normoxia unclear","Single-lab finding"]},{"year":2024,"claim":"Defined the autophagy-suppressing function of VHL through binding hydroxylated Beclin1 to block VPS34–ATG14L assembly.","evidence":"VHL–Beclin1 Co-IP, PHD1 hydroxylation, Pro54 mutagenesis, VPS34 pull-down, and autophagy flux assays","pmids":["38360997"],"confidence":"High","gaps":["Whether Beclin1 is also ubiquitinated/degraded vs. only sequestered not fully addressed","In vivo autophagy consequences in VHL-disease tissue not characterized"]},{"year":2024,"claim":"Showed metabolite-driven lactylation of HIF-1α sterically blocks VHL binding without affecting prolyl hydroxylation, defining a metabolism-coupled escape from degradation.","evidence":"MS lactylation mapping, mutagenesis, K48 ubiquitination, VHL Co-IP, and ChIP","pmids":["40760493"],"confidence":"Medium","gaps":["Enzymes catalyzing/removing HIF-1α lactylation not defined here","Single-lab finding"]},{"year":2024,"claim":"Showed UBE2S adds K11-linked polyubiquitin to VHL K171/K196 independently of an E3, degrading VHL and indirectly stabilizing HIF-1α in HCC.","evidence":"Co-IP, K11-specific ubiquitination, VHL stability, and glycolysis assays","pmids":["38915206"],"confidence":"Medium","gaps":["How an E2 acts E3-independently on VHL mechanistically unresolved","Single-lab finding"]},{"year":2024,"claim":"Built a comprehensive functional variant map distinguishing ccRCC- from pheochromocytoma-associated alleles and revealing mRNA-dosage mechanisms of pathogenicity.","evidence":"Saturation genome editing of 2,268 variants with functional selection and mRNA quantification","pmids":["38969834"],"confidence":"High","gaps":["Mechanistic basis of phenotype-specific allele effects not fully explained","Functional scores derived in selected cell systems"]},{"year":2025,"claim":"Demonstrated the HIF1α-binding pocket on pVHL can be redirected by a molecular-glue degrader to recruit and degrade neosubstrates such as CDO1, providing a structural basis for VHL-based degraders.","evidence":"Protein array screening, docking/MD, X-ray crystallography of the ternary VHL–CDO1–degrader complex, and cellular degradation","pmids":["40555806"],"confidence":"High","gaps":["Generalizability to other neosubstrates not established","In vivo efficacy not addressed"]},{"year":null,"claim":"It remains unresolved how the many competing substrates and regulators of pVHL are prioritized in vivo and whether non-HIF substrates require proline hydroxylation as a universal recognition rule.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model integrating spindle, repair, mitochondrial, and ligase functions","Substrate recognition determinants beyond hydroxyproline not generalized","Tissue-specific substrate hierarchy unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[0,16,17,19,20]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,17,20]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,8]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[19,17]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[1,26]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[7]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6,7]}],"pathway":[{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[0]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,8,16,17,19,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[25,27]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[19]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[14,4]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[1,26]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[6,25]}],"complexes":["CRL2VHL (pVHL–Elongin B/C–Cullin2–RING E3 ligase)"],"partners":["HIF1A","ELOB","ELOC","CUL2","ID2","DAAM2","BECN1","TBK1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P40337","full_name":"von Hippel-Lindau disease tumor suppressor","aliases":["Protein G7","pVHL"],"length_aa":213,"mass_kda":24.2,"function":"Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex (PubMed:10944113, PubMed:17981124, PubMed:19584355). Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions (PubMed:10944113, PubMed:17981124). Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases (PubMed:10944113, PubMed:17981124). Ubiquitinates, in an oxygen-responsive manner, ADRB2 (PubMed:19584355). Acts as a negative regulator of mTORC1 by promoting ubiquitination and degradation of RPTOR (PubMed:34290272)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P40337/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/VHL","classification":"Common Essential","n_dependent_lines":931,"n_total_lines":1208,"dependency_fraction":0.7706953642384106},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000134086","cell_line_id":"CID000259","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":3}],"interactors":[],"url":"https://opencell.sf.czbiohub.org/target/CID000259","total_profiled":1310},"omim":[{"mim_id":"619650","title":"VHL-LIKE PROTEIN; VHLL","url":"https://www.omim.org/entry/619650"},{"mim_id":"618359","title":"ZINC FINGER PROTEIN 197; ZNF197","url":"https://www.omim.org/entry/618359"},{"mim_id":"617764","title":"ZYG11-RELATED CELL CYCLE REGULATOR; ZER1","url":"https://www.omim.org/entry/617764"},{"mim_id":"617679","title":"KELCH-LIKE 20; KLHL20","url":"https://www.omim.org/entry/617679"},{"mim_id":"615146","title":"UBIQUITIN-SPECIFIC PROTEASE 33; USP33","url":"https://www.omim.org/entry/615146"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Microtubules","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Primary cilium tip","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/VHL"},"hgnc":{"alias_symbol":["VHL1"],"prev_symbol":[]},"alphafold":{"accession":"P40337","domains":[{"cath_id":"2.60.40.780","chopping":"70-156_187-211","consensus_level":"medium","plddt":97.3129,"start":70,"end":211}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P40337","model_url":"https://alphafold.ebi.ac.uk/files/AF-P40337-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P40337-F1-predicted_aligned_error_v6.png","plddt_mean":84.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=VHL","jax_strain_url":"https://www.jax.org/strain/search?query=VHL"},"sequence":{"accession":"P40337","fasta_url":"https://rest.uniprot.org/uniprotkb/P40337.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P40337/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P40337"}},"corpus_meta":[{"pmid":"11292862","id":"PMC_11292862","title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.","date":"2001","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11292862","citation_count":3948,"is_preprint":false},{"pmid":"7915601","id":"PMC_7915601","title":"Mutations of the VHL tumour suppressor gene in renal carcinoma.","date":"1994","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7915601","citation_count":1506,"is_preprint":false},{"pmid":"7937876","id":"PMC_7937876","title":"Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7937876","citation_count":1360,"is_preprint":false},{"pmid":"15611513","id":"PMC_15611513","title":"Role of VHL gene mutation in human cancer.","date":"2004","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15611513","citation_count":752,"is_preprint":false},{"pmid":"25533676","id":"PMC_25533676","title":"VHL, the story of a tumour suppressor gene.","date":"2015","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25533676","citation_count":621,"is_preprint":false},{"pmid":"22705278","id":"PMC_22705278","title":"The VHL/HIF axis in clear cell renal carcinoma.","date":"2012","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/22705278","citation_count":322,"is_preprint":false},{"pmid":"20225241","id":"PMC_20225241","title":"VHL and HIF signalling in renal cell carcinogenesis.","date":"2010","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20225241","citation_count":258,"is_preprint":false},{"pmid":"32948771","id":"PMC_32948771","title":"Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32948771","citation_count":244,"is_preprint":false},{"pmid":"16585181","id":"PMC_16585181","title":"Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16585181","citation_count":229,"is_preprint":false},{"pmid":"9820032","id":"PMC_9820032","title":"The VHL tumour-suppressor gene paradigm.","date":"1998","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/9820032","citation_count":192,"is_preprint":false},{"pmid":"35983982","id":"PMC_35983982","title":"Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.","date":"2022","source":"Chemical Society reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35983982","citation_count":171,"is_preprint":false},{"pmid":"36216795","id":"PMC_36216795","title":"A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36216795","citation_count":170,"is_preprint":false},{"pmid":"15776016","id":"PMC_15776016","title":"VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha.","date":"2005","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/15776016","citation_count":168,"is_preprint":false},{"pmid":"20368728","id":"PMC_20368728","title":"Alterations in VHL as potential biomarkers in renal-cell carcinoma.","date":"2010","source":"Nature reviews. Clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20368728","citation_count":145,"is_preprint":false},{"pmid":"19671042","id":"PMC_19671042","title":"The VHL tumor suppressor: master regulator of HIF.","date":"2009","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/19671042","citation_count":144,"is_preprint":false},{"pmid":"16531988","id":"PMC_16531988","title":"The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease.","date":"2006","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/16531988","citation_count":135,"is_preprint":false},{"pmid":"28893800","id":"PMC_28893800","title":"VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma.","date":"2017","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/28893800","citation_count":135,"is_preprint":false},{"pmid":"18219317","id":"PMC_18219317","title":"The VHL tumor suppressor and HIF: insights from genetic studies in mice.","date":"2008","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/18219317","citation_count":131,"is_preprint":false},{"pmid":"19620968","id":"PMC_19620968","title":"VHL loss causes spindle misorientation and chromosome instability.","date":"2009","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19620968","citation_count":130,"is_preprint":false},{"pmid":"30826187","id":"PMC_30826187","title":"Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.","date":"2019","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30826187","citation_count":113,"is_preprint":false},{"pmid":"11987242","id":"PMC_11987242","title":"Endemic polycythemia in Russia: mutation in the VHL gene.","date":"2002","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/11987242","citation_count":109,"is_preprint":false},{"pmid":"26735018","id":"PMC_26735018","title":"An ID2-dependent mechanism for VHL inactivation in cancer.","date":"2016","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26735018","citation_count":105,"is_preprint":false},{"pmid":"19402056","id":"PMC_19402056","title":"Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein.","date":"2009","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19402056","citation_count":104,"is_preprint":false},{"pmid":"28790514","id":"PMC_28790514","title":"The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.","date":"2017","source":"Transactions of the American Clinical and Climatological Association","url":"https://pubmed.ncbi.nlm.nih.gov/28790514","citation_count":100,"is_preprint":false},{"pmid":"29562667","id":"PMC_29562667","title":"VHL and Hypoxia Signaling: Beyond HIF in Cancer.","date":"2018","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/29562667","citation_count":98,"is_preprint":false},{"pmid":"31810986","id":"PMC_31810986","title":"TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss.","date":"2019","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/31810986","citation_count":94,"is_preprint":false},{"pmid":"29229903","id":"PMC_29229903","title":"Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29229903","citation_count":85,"is_preprint":false},{"pmid":"34575959","id":"PMC_34575959","title":"Loss of Von Hippel-Lindau (VHL) Tumor Suppressor Gene Function: VHL-HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC).","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34575959","citation_count":81,"is_preprint":false},{"pmid":"22299048","id":"PMC_22299048","title":"Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cysts.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22299048","citation_count":76,"is_preprint":false},{"pmid":"23606570","id":"PMC_23606570","title":"Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice.","date":"2013","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23606570","citation_count":75,"is_preprint":false},{"pmid":"28925400","id":"PMC_28925400","title":"The HIF and other quandaries in VHL disease.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28925400","citation_count":72,"is_preprint":false},{"pmid":"22125026","id":"PMC_22125026","title":"Role of VHL gene mutation in human renal cell carcinoma.","date":"2011","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22125026","citation_count":71,"is_preprint":false},{"pmid":"31575731","id":"PMC_31575731","title":"HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.","date":"2019","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/31575731","citation_count":70,"is_preprint":false},{"pmid":"25589003","id":"PMC_25589003","title":"Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.","date":"2014","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/25589003","citation_count":67,"is_preprint":false},{"pmid":"19493342","id":"PMC_19493342","title":"CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma.","date":"2009","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19493342","citation_count":66,"is_preprint":false},{"pmid":"22673568","id":"PMC_22673568","title":"Systemic VHL gene functions and the VHL disease.","date":"2012","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/22673568","citation_count":65,"is_preprint":false},{"pmid":"20864688","id":"PMC_20864688","title":"VHL inactivation induces HEF1 and Aurora kinase A.","date":"2010","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/20864688","citation_count":57,"is_preprint":false},{"pmid":"19764026","id":"PMC_19764026","title":"Genotype-phenotype correlations in VHL exon deletions.","date":"2009","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/19764026","citation_count":57,"is_preprint":false},{"pmid":"34656901","id":"PMC_34656901","title":"VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.","date":"2021","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34656901","citation_count":54,"is_preprint":false},{"pmid":"17218907","id":"PMC_17218907","title":"Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.","date":"2007","source":"Retina (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/17218907","citation_count":51,"is_preprint":false},{"pmid":"22020339","id":"PMC_22020339","title":"JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22020339","citation_count":49,"is_preprint":false},{"pmid":"16969113","id":"PMC_16969113","title":"The positive regulation of p53 by the tumor suppressor VHL.","date":"2006","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/16969113","citation_count":47,"is_preprint":false},{"pmid":"20833332","id":"PMC_20833332","title":"VHL disease.","date":"2010","source":"Best practice & research. Clinical endocrinology & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20833332","citation_count":46,"is_preprint":false},{"pmid":"23318261","id":"PMC_23318261","title":"Proteostasis modulators prolong missense VHL protein activity and halt tumor progression.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23318261","citation_count":46,"is_preprint":false},{"pmid":"16925945","id":"PMC_16925945","title":"Ubiquitin pathway in VHL cancer syndrome.","date":"2006","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16925945","citation_count":45,"is_preprint":false},{"pmid":"11705642","id":"PMC_11705642","title":"Clinical management of Von Hippel-Lindau (VHL) disease.","date":"2001","source":"The Netherlands journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11705642","citation_count":45,"is_preprint":false},{"pmid":"20844582","id":"PMC_20844582","title":"Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20844582","citation_count":45,"is_preprint":false},{"pmid":"37224698","id":"PMC_37224698","title":"A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.","date":"2023","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37224698","citation_count":44,"is_preprint":false},{"pmid":"38969834","id":"PMC_38969834","title":"Saturation genome editing maps the functional spectrum of pathogenic VHL alleles.","date":"2024","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38969834","citation_count":41,"is_preprint":false},{"pmid":"23455319","id":"PMC_23455319","title":"K63-ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23455319","citation_count":40,"is_preprint":false},{"pmid":"24899725","id":"PMC_24899725","title":"Regulation of the VHL/HIF-1 pathway by DJ-1.","date":"2014","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24899725","citation_count":38,"is_preprint":false},{"pmid":"36749883","id":"PMC_36749883","title":"Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.","date":"2023","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/36749883","citation_count":37,"is_preprint":false},{"pmid":"25866969","id":"PMC_25866969","title":"Pharmacological HIF2α inhibition improves VHL disease-associated phenotypes in zebrafish model.","date":"2015","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/25866969","citation_count":36,"is_preprint":false},{"pmid":"33329393","id":"PMC_33329393","title":"The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33329393","citation_count":35,"is_preprint":false},{"pmid":"17932373","id":"PMC_17932373","title":"The HIF/VHL pathway: from oxygen sensing to innate immunity.","date":"2007","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17932373","citation_count":35,"is_preprint":false},{"pmid":"17102089","id":"PMC_17102089","title":"Transcription association of VHL and SDH mutations link hypoxia and oxidoreductase signals in pheochromocytomas.","date":"2006","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17102089","citation_count":35,"is_preprint":false},{"pmid":"38478885","id":"PMC_38478885","title":"Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACs.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38478885","citation_count":32,"is_preprint":false},{"pmid":"24201123","id":"PMC_24201123","title":"Renal cell carcinoma with smooth muscle stroma lacks chromosome 3p and VHL alterations.","date":"2013","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/24201123","citation_count":32,"is_preprint":false},{"pmid":"37183204","id":"PMC_37183204","title":"Development of VHL-recruiting STING PROTACs that suppress innate immunity.","date":"2023","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/37183204","citation_count":31,"is_preprint":false},{"pmid":"32936333","id":"PMC_32936333","title":"Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease.","date":"2020","source":"World journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/32936333","citation_count":31,"is_preprint":false},{"pmid":"12114475","id":"PMC_12114475","title":"Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter.","date":"2002","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12114475","citation_count":31,"is_preprint":false},{"pmid":"24145437","id":"PMC_24145437","title":"BC-box protein domain-related mechanism for VHL protein degradation.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24145437","citation_count":30,"is_preprint":false},{"pmid":"19340311","id":"PMC_19340311","title":"Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19340311","citation_count":30,"is_preprint":false},{"pmid":"34174286","id":"PMC_34174286","title":"Von Hippel-Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34174286","citation_count":29,"is_preprint":false},{"pmid":"32792353","id":"PMC_32792353","title":"The Daam2-VHL-Nedd4 axis governs developmental and regenerative oligodendrocyte differentiation.","date":"2020","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/32792353","citation_count":29,"is_preprint":false},{"pmid":"35205407","id":"PMC_35205407","title":"The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/35205407","citation_count":28,"is_preprint":false},{"pmid":"34290272","id":"PMC_34290272","title":"VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34290272","citation_count":28,"is_preprint":false},{"pmid":"29720560","id":"PMC_29720560","title":"Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism.","date":"2018","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/29720560","citation_count":27,"is_preprint":false},{"pmid":"33400184","id":"PMC_33400184","title":"Relationship between visceral adipose tissue and genetic mutations (VHL and KDM5C) in clear cell renal cell carcinoma.","date":"2021","source":"La Radiologia medica","url":"https://pubmed.ncbi.nlm.nih.gov/33400184","citation_count":27,"is_preprint":false},{"pmid":"39693386","id":"PMC_39693386","title":"Impact of Linker Composition on VHL PROTAC Cell Permeability.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39693386","citation_count":26,"is_preprint":false},{"pmid":"38199162","id":"PMC_38199162","title":"Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.","date":"2023","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38199162","citation_count":26,"is_preprint":false},{"pmid":"24362914","id":"PMC_24362914","title":"Tumor suppressor VHL functions in the control of mitotic fidelity.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24362914","citation_count":26,"is_preprint":false},{"pmid":"40760493","id":"PMC_40760493","title":"Lactylation modification of HIF-1α enhances its stability by blocking VHL recognition.","date":"2025","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/40760493","citation_count":24,"is_preprint":false},{"pmid":"32076485","id":"PMC_32076485","title":"Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes.","date":"2020","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/32076485","citation_count":24,"is_preprint":false},{"pmid":"17245122","id":"PMC_17245122","title":"The role of VHL in the regulation of E-cadherin: a new connection in an old pathway.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17245122","citation_count":24,"is_preprint":false},{"pmid":"35231578","id":"PMC_35231578","title":"Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases.","date":"2022","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/35231578","citation_count":24,"is_preprint":false},{"pmid":"40555806","id":"PMC_40555806","title":"A small-molecule VHL molecular glue degrader for cysteine dioxygenase 1.","date":"2025","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/40555806","citation_count":23,"is_preprint":false},{"pmid":"30338240","id":"PMC_30338240","title":"VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function.","date":"2018","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30338240","citation_count":23,"is_preprint":false},{"pmid":"18818511","id":"PMC_18818511","title":"Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics.","date":"2008","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/18818511","citation_count":23,"is_preprint":false},{"pmid":"29373688","id":"PMC_29373688","title":"Compromised JMJD6 Histone Demethylase Activity Affects VHL Gene Repression in Preeclampsia.","date":"2018","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29373688","citation_count":22,"is_preprint":false},{"pmid":"38915206","id":"PMC_38915206","title":"UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL.","date":"2024","source":"Clinical and molecular hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/38915206","citation_count":21,"is_preprint":false},{"pmid":"30413999","id":"PMC_30413999","title":"Immune regulation by protein ubiquitination: roles of the E3 ligases VHL and Itch.","date":"2018","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/30413999","citation_count":21,"is_preprint":false},{"pmid":"29053101","id":"PMC_29053101","title":"Daam2 driven degradation of VHL promotes gliomagenesis.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/29053101","citation_count":21,"is_preprint":false},{"pmid":"27126173","id":"PMC_27126173","title":"Combined deletion of Vhl, Trp53 and Kif3a causes cystic and neoplastic renal lesions.","date":"2016","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27126173","citation_count":21,"is_preprint":false},{"pmid":"38360997","id":"PMC_38360997","title":"VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation.","date":"2024","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/38360997","citation_count":20,"is_preprint":false},{"pmid":"25500545","id":"PMC_25500545","title":"RSUME inhibits VHL and regulates its tumor suppressor function.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25500545","citation_count":20,"is_preprint":false},{"pmid":"23178531","id":"PMC_23178531","title":"Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.","date":"2012","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/23178531","citation_count":20,"is_preprint":false},{"pmid":"16387411","id":"PMC_16387411","title":"Determination of vhl gene mutations in sporadic renal cell carcinoma.","date":"2005","source":"European urology","url":"https://pubmed.ncbi.nlm.nih.gov/16387411","citation_count":20,"is_preprint":false},{"pmid":"16713574","id":"PMC_16713574","title":"VHL and p53: tumor suppressors team up to prevent cancer.","date":"2006","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16713574","citation_count":20,"is_preprint":false},{"pmid":"28868236","id":"PMC_28868236","title":"Management Strategies and Outcomes for VHL-related Craniospinal Hemangioblastomas.","date":"2017","source":"Journal of kidney cancer and VHL","url":"https://pubmed.ncbi.nlm.nih.gov/28868236","citation_count":19,"is_preprint":false},{"pmid":"31613797","id":"PMC_31613797","title":"Rb1/Rbl1/Vhl loss induces mouse subretinal angiomatous proliferation and hemangioblastoma.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31613797","citation_count":19,"is_preprint":false},{"pmid":"38755248","id":"PMC_38755248","title":"Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs.","date":"2024","source":"Communications medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38755248","citation_count":19,"is_preprint":false},{"pmid":"28036268","id":"PMC_28036268","title":"Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28036268","citation_count":17,"is_preprint":false},{"pmid":"16101382","id":"PMC_16101382","title":"Molecular targets from VHL studies into the oxygen-sensing pathway.","date":"2005","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/16101382","citation_count":16,"is_preprint":false},{"pmid":"29463811","id":"PMC_29463811","title":"Consequences of VHL Loss on Global DNA Methylome.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29463811","citation_count":16,"is_preprint":false},{"pmid":"29425832","id":"PMC_29425832","title":"Small activating RNA induced expression of VHL gene in renal cell carcinoma.","date":"2018","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29425832","citation_count":15,"is_preprint":false},{"pmid":"25027579","id":"PMC_25027579","title":"Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma.","date":"2014","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25027579","citation_count":15,"is_preprint":false},{"pmid":"35304467","id":"PMC_35304467","title":"VHL mosaicism: the added value of multi-tissue analysis.","date":"2022","source":"NPJ genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35304467","citation_count":15,"is_preprint":false},{"pmid":"35169254","id":"PMC_35169254","title":"iASPP is essential for HIF-1α stabilization to promote angiogenesis and glycolysis via attenuating VHL-mediated protein degradation.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35169254","citation_count":15,"is_preprint":false},{"pmid":"31436504","id":"PMC_31436504","title":"VHL Synthetic Lethality Signatures Uncovered by Genotype-Specific CRISPR-Cas9 Screens.","date":"2019","source":"The CRISPR journal","url":"https://pubmed.ncbi.nlm.nih.gov/31436504","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43532,"output_tokens":7296,"usd":0.120018,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16898,"output_tokens":7392,"usd":0.134645,"stage2_stop_reason":"end_turn"},"total_usd":0.254663,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"pVHL binds to a short HIF-derived peptide only when a conserved proline residue is hydroxylated; proline hydroxylation requires molecular oxygen and Fe2+, establishing pVHL as the oxygen-sensitive substrate-recognition component of an E3 ubiquitin ligase that targets HIFα for proteasomal destruction.\",\n      \"method\": \"Peptide-binding assay with hydroxylated vs. non-hydroxylated HIF-derived peptides; functional ubiquitination assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct biochemical binding assay with hydroxylated peptides, reconstituted the oxygen-dependent recognition mechanism, widely replicated across multiple labs\",\n      \"pmids\": [\"11292862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"pVHL localizes to the mitotic spindle in mammalian cells; its functional inactivation causes spindle misorientation via unstable astral microtubules, reduced Mad2 levels leading to spindle checkpoint weakening, and chromosomal instability. Restoration of wild-type pVHL (but not microtubule-stabilization-defective VHL disease mutants) rescued spindle misorientation.\",\n      \"method\": \"Immunofluorescence localization to mitotic spindle; VHL re-expression rescue experiments; Mad2 knockdown/overexpression epistasis; analysis of VHL disease mutants; aneuploidy scoring in human renal cancer\",\n      \"journal\": \"Nature Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (localization, rescue with WT vs. mutant pVHL, genetic epistasis with Mad2), corroborated in human tumor tissue\",\n      \"pmids\": [\"19620968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"VHL-interacting deubiquitinating enzyme 2 (VDU2), but not VDU1, interacts with HIF-1α and specifically deubiquitinates and stabilizes it, counteracting pVHL-mediated ubiquitination, thereby increasing HIF-1α target gene expression (e.g., VEGF).\",\n      \"method\": \"Co-immunoprecipitation (VDU2–HIF-1α interaction); in vivo deubiquitination assay; reporter gene assays for VEGF expression\",\n      \"journal\": \"EMBO Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and functional deubiquitination assay in single lab, two orthogonal methods\",\n      \"pmids\": [\"15776016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"pVHL directly associates with and positively regulates tumor suppressor p53 by inhibiting Mdm2-mediated ubiquitination of p53 and by recruiting p53-modifying enzymes; VHL-deleted RCC cells show attenuated DNA-damage response that is restored by pVHL re-expression.\",\n      \"method\": \"Co-immunoprecipitation (pVHL–p53 interaction); ubiquitination assays; cell-cycle and apoptosis assays in VHL-null vs. pVHL-restored RCC cells\",\n      \"journal\": \"Cell Cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination assay, and functional rescue in single lab with multiple orthogonal readouts\",\n      \"pmids\": [\"16969113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"VHL inactivation suppresses E-cadherin expression through HIF activation; HIF activation is both necessary and sufficient to suppress E-cadherin in renal cancer cells, and VHL re-expression in VHL-defective RCC lines restores E-cadherin.\",\n      \"method\": \"VHL re-expression in RCC4 and RCC10 cell lines; HIF activation experiments; E-cadherin expression assays by western blot/immunostaining\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional rescue with VHL re-expression and epistasis showing HIF requirement, single lab with multiple methods\",\n      \"pmids\": [\"16585181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"VHL inactivation induces HEF1/NEDD9 and Aurora kinase A via HIF-1 and HIF-2 stabilization; Aurora kinase A promotes primary cilium regression via HDAC-dependent tubulin depolymerization, and HEF1 at the centrosome enhances this effect. Suppression of this pathway improved primary cilium formation and reduced cell motility in VHL-defective cells.\",\n      \"method\": \"Gene expression analysis; knockdown/overexpression experiments in VHL-defective renal cancer cells; cilium formation assays; cell motility assays\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function experiments with defined phenotypic readouts (ciliation, motility), pathway placement via HIF epistasis, single lab\",\n      \"pmids\": [\"20864688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SOCS1 promotes K63-ubiquitylation of VHL in response to DNA double-strand breaks (DSBs), causing nuclear redistribution of VHL; loss of VHL or VHL mutations that compromise K63-ubiquitylation attenuates homologous recombination repair and increases persistence of DSBs.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays (K63-specific); DNA damage assays (γH2AX foci, comet assay); nuclear fractionation; HR repair assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical methods (Co-IP, K63 ubiquitination, HR assay), functional link to DNA repair established, single lab\",\n      \"pmids\": [\"23455319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"VHL undergoes ubiquitylation at lysine residues 171 and 196, which destabilizes VHL and promotes cytoplasmic localization; SUMOylation at K171 (mediated by PIASy) blocks ubiquitylation, increases VHL stability, and promotes nuclear redistribution. Mutation of K171 and K196 to arginine abrogates VHL's inhibitory function on HIFα transcriptional activity.\",\n      \"method\": \"VHL-SUMO1/ubiquitin fusion proteins; subcellular fractionation; reporter assays for HIFα transcriptional activity; tube formation assay\",\n      \"journal\": \"PLoS ONE\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis with functional readouts (HIFα activity, tube formation), localization data, single lab\",\n      \"pmids\": [\"20844582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Adenoviral Gam1 protein, via its BC-box domain competing with VHL for Elongin B/C binding, induces VHL proteasomal degradation through a CRL-dependent mechanism, leading to HIF-1α stabilization; cellular BC-box proteins and SOCS domain-containing viral proteins can similarly drive VHL degradation.\",\n      \"method\": \"Co-immunoprecipitation; proteasome inhibitor rescue experiments; HIF-1α reporter assays; domain mapping with BC-box mutants\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, domain mapping, functional reporter assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"24145437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"DJ-1 (PARK7) interacts with VHL protein and negatively regulates VHL's ubiquitination activity toward HIF-1α by inhibiting the HIF–VHL interaction; DJ-1 deficiency leads to lowered HIF-1α levels under hypoxia and oxidative stress, and HIF-1α accumulation rescues DJ-1-deficient neurons from toxicity.\",\n      \"method\": \"Co-immunoprecipitation (DJ-1–VHL); HIF-1α ubiquitination and stability assays; HIF-1α accumulation assays in knockout models; neuroprotection assays\",\n      \"journal\": \"Journal of Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and functional ubiquitination assays, single lab, multiple methods\",\n      \"pmids\": [\"24899725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ID2 binds to the VHL ubiquitin ligase complex, displaces VHL-associated Cullin 2, and impairs HIF2α ubiquitylation and degradation. DYRK1A/B phosphorylation of ID2 at Thr27 (stimulated by PHD1/EGLN2 in normoxia) blocks the ID2–VHL interaction, preserving HIF2α ubiquitylation.\",\n      \"method\": \"Co-immunoprecipitation (ID2–VHL complex); ubiquitination assays for HIF2α; kinase assays (DYRK1A/B phosphorylation of ID2); phospho-site mutagenesis; glioma xenograft models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical reconstitution of the ID2-VHL interaction, site-specific mutagenesis of Thr27, kinase assays, and in vivo xenograft validation in one rigorous study\",\n      \"pmids\": [\"26735018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Missense mutant pVHL retains E3 ligase function (including HIFα degradation) but is unstable due to misfolding and imbalance of chaperonin binding; HDAC inhibitors stabilize missense pVHL by modulating the HDAC-Hsp90 chaperone axis, restoring activity comparable to wild-type protein.\",\n      \"method\": \"In vitro E3 ligase assays; chaperone interaction studies; HDACI treatment with protein stability measurements; xenograft tumor growth assays\",\n      \"journal\": \"Cell Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro E3 ligase assay combined with chaperone interaction studies and in vivo rescue, single lab\",\n      \"pmids\": [\"23318261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RSUME physically interacts with pVHL, sumoylates it, and negatively regulates assembly of the pVHL–Elongin–Cullin (ECV) complex, thereby inhibiting HIF-1α and HIF-2α ubiquitination and degradation; RSUME is required for the loss-of-function of type 2 pVHL mutants.\",\n      \"method\": \"Co-immunoprecipitation (RSUME–pVHL); SUMOylation assays; ECV assembly assays; HIF ubiquitination assays; HIF stability reporter; xenograft assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, SUMOylation assay, ubiquitination assay, and in vivo xenograft, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"25500545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Daam2 associates with VHL and facilitates its ubiquitination and proteasomal degradation, providing a non-mutational mechanism of VHL suppression in glioma; inverse correlation between Daam2 and VHL expression was found across cancers including glioma.\",\n      \"method\": \"Co-immunoprecipitation (Daam2–VHL); ubiquitination assays; VHL protein stability measurements; tumor growth assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination assay, functional tumor growth assay, single lab\",\n      \"pmids\": [\"29053101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"VHL loss stabilizes HIF2α–HIF1β heterodimer binding at enhancers, subsequently recruiting histone acetyltransferase p300 to acquire active enhancer marks (H3K27ac, H3K4me1) near ccRCC hallmark genes, driving enhancer/superenhancer deregulation without overtly affecting preexisting promoter–enhancer interactions.\",\n      \"method\": \"ChIP-seq (H3K27ac, H3K4me1, HIF2α, p300); chromatin profiling in 10 primary tumor/normal pairs and 9 cell lines; VHL loss-of-function genetic models\",\n      \"journal\": \"Cancer Discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq across large sample set with multiple histone marks and transcription factor binding, mechanistic link to p300 recruitment established, single lab\",\n      \"pmids\": [\"28893800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"pVHL re-expression in pVHL-defective renal carcinoma cells elevates CHCHD4 (a mitochondrial intermembrane space protein import component) and respiratory chain subunits (NDUFB10, mtCO-2, COX IV), enhancing oxygen consumption rate; this effect is distinct from HIF-α regulation and is also recapitulated by HIF-2α knockdown.\",\n      \"method\": \"VHL re-expression in 786O and RCC10 cells; oxygen consumption rate measurements; western blot for respiratory chain subunits; metabolic profiling; mitochondrial morphology analysis\",\n      \"journal\": \"Frontiers in Oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional rescue with VHL re-expression and HIF-2α knockdown, multiple metabolic readouts, single lab\",\n      \"pmids\": [\"30338240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TBK1 hydroxylation on Proline 48 triggers VHL binding (as well as phosphatase PPM1B binding), leading to decreased TBK1 phosphorylation; in the absence of VHL, TBK1 is hyperactivated and phosphorylates p62/SQSTM1 on Ser366, which is essential for p62 stability and kidney cancer cell proliferation.\",\n      \"method\": \"Co-immunoprecipitation (VHL–TBK1); hydroxylation assays; phosphorylation assays; VHL loss-of-function studies; xenograft models\",\n      \"journal\": \"Cancer Discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, hydroxylation and phosphorylation assays, in vivo xenograft, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"31810986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"VHL interacts with RAPTOR (regulatory-associated protein of mTOR) and increases RAPTOR degradation by ubiquitination, thereby inhibiting mTORC1 signaling; loss of vhl-1 in C. elegans increases mTORC1 activity, supporting evolutionary conservation of this mechanism.\",\n      \"method\": \"Co-immunoprecipitation (VHL–RAPTOR); ubiquitination assays; mTORC1 activity assays; C. elegans vhl-1 loss-of-function genetics\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination assay, functional mTORC1 readout, cross-species genetic validation, single lab\",\n      \"pmids\": [\"34290272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The E3 ligase VHL interacts with Daam2, and their mutual antagonism regulates oligodendrocyte differentiation during development; the E3 ubiquitin ligase Nedd4 stabilizes VHL via K63-linked ubiquitination. This Daam2-VHL-Nedd4 axis is required for developmental myelination and remyelination after white matter injury.\",\n      \"method\": \"Proteomic analysis of Daam2–VHL complex; co-immunoprecipitation; conditional knockout mouse models; K63 ubiquitination assays; demyelination mouse models; human MS lesion analysis\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — proteomic complex analysis, Co-IP, K63 ubiquitination assay, conditional KO mice, and human disease tissue corroboration across multiple orthogonal methods\",\n      \"pmids\": [\"32792353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"VHL suppresses autophagy by directly binding to Beclin1 after PHD1-mediated hydroxylation of Beclin1 on Pro54; this binding inhibits the Beclin1–VPS34 complex association with ATG14L, blocking autophagy initiation. Non-hydroxylatable Beclin1-P54A abrogates VHL-mediated autophagy inhibition.\",\n      \"method\": \"Co-immunoprecipitation (VHL–Beclin1); PHD1 hydroxylation assays; Pro54 site-directed mutagenesis; VPS34 complex pull-down; autophagy flux assays; xenograft tumor models\",\n      \"journal\": \"The EMBO Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct binding assay, hydroxylation assay, site-directed mutagenesis of the critical proline, and complex assembly assay in one rigorous study\",\n      \"pmids\": [\"38360997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"VHL acts as a bona fide E3 ligase for STING in renal cell carcinoma; VHL-recruiting STING PROTACs further promote VHL-dependent STING degradation, and locking STING on the endoplasmic reticulum via mutagenesis blocks its translocation to the proteasome and prevents degradation.\",\n      \"method\": \"PROTAC-mediated degradation assays; STING localization mutagenesis (ER retention); co-immunoprecipitation; downstream innate immune signaling assays\",\n      \"journal\": \"Cellular and Molecular Life Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, degradation assay, mutagenesis-based localization rescue, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"37183204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Lactylation of HIF-1α at K644 (mouse) or K12 (human/pig) reduces K48-linked ubiquitination and proteasomal degradation by sterically hindering VHL binding without affecting prolyl hydroxylation of HIF-1α; lactylated HIF-1α retains increased transcriptional activity (elevated VEGFA, GLUT1 promoter occupancy).\",\n      \"method\": \"Mass spectrometry identification of lactylation sites; site-directed mutagenesis; K48 ubiquitination assays; VHL co-immunoprecipitation with lactylated vs. non-lactylated HIF-1α; structural modeling; chromatin immunoprecipitation\",\n      \"journal\": \"Cell Communication and Signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis, MS-based modification identification, ubiquitination assays, and VHL binding assays in single lab with multiple orthogonal methods\",\n      \"pmids\": [\"40760493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"UBE2S promotes K11-linkage polyubiquitination of VHL at lysine residues 171 and 196 independently of E3 ligase activity, mediating VHL proteasomal degradation and indirectly stabilizing HIF-1α to promote glycolysis in hepatocellular carcinoma.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays (K11-specific); VHL stability measurements; glycolysis assays; HIF-1α protein level analysis\",\n      \"journal\": \"Clinical and Molecular Hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, specific K11 ubiquitination assay, functional glycolysis and HIF-1α stability readouts, single lab\",\n      \"pmids\": [\"38915206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"iASPP directly binds to the β domain of VHL (the region involved in HIF-1α binding), blocking VHL's binding to and degradation of HIF-1α under normoxia, thereby promoting angiogenesis and glycolysis in VHL wild-type tumors.\",\n      \"method\": \"Co-immunoprecipitation (iASPP–VHL); domain mapping (β domain); HIF-1α ubiquitination and stability assays; in vitro binding competition assays; tumor xenograft models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping, ubiquitination competition assay, in vivo xenograft, single lab\",\n      \"pmids\": [\"35169254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"VHL inhibitor VH298 stabilizes VHL protein isoforms (without changing transcript levels), which in turn reduces HIF-1α protein levels, demonstrating a negative feedback mechanism where VHL inhibitor-mediated blocking of the VHL–HIF-α interaction paradoxically increases VHL protein abundance.\",\n      \"method\": \"Quantitative mass spectrometry proteomics; VHL stability assays (cycloheximide chase); transcript level analysis; HIF-1α western blot after VH298 treatment\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative MS proteomics combined with functional protein stability assays, single lab, two orthogonal methods\",\n      \"pmids\": [\"34174286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"VHL loss alone causes DNA replication stress and DNA damage accumulation in renal epithelial cells, constraining proliferation; concomitant loss of PBRM1 rescues VHL-induced replication stress and allows proliferation. Combined deletion of Vhl and Pbrm1 in mouse kidney is sufficient for fully-penetrant, multifocal carcinoma development.\",\n      \"method\": \"DNA damage markers (γH2AX); replication stress assays; conditional mouse knockout (Vhl, Pbrm1, or both); histopathological analysis of kidney tumors\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in mouse KO models with defined molecular readout (replication stress), corroborated in human tumor context\",\n      \"pmids\": [\"29229903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Tumor suppressor VHL is required for proper spindle orientation and mitotic checkpoint fidelity in vivo: Vhl-deficient kidney cells after ischemic injury demonstrate spindle misorientation and aneuploidy (lagging chromosomes, indicating checkpoint impairment) within days, followed by ccRCC precursor lesion development at 4 months.\",\n      \"method\": \"Ischemic kidney injury model; conditional Vhl knockout mice; immunofluorescence for spindle orientation; FISH for aneuploidy; histopathological analysis\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo conditional knockout with defined mitotic phenotypes corroborating earlier in vitro findings, multiple orthogonal readouts\",\n      \"pmids\": [\"24362914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Saturation genome editing of VHL's entire coding sequence quantified functional effects of 2,268 VHL single-nucleotide variants; function scores identified a core set of pathogenic alleles driving ccRCC, distinguished from pheochromocytoma-associated alleles, and revealed that some variants impact VHL function through mRNA dosage effects rather than protein dysfunction.\",\n      \"method\": \"Saturation genome editing (base editing + selection); mRNA quantification; comparison across isogenic cell lines; functional score calculation\",\n      \"journal\": \"Nature Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — saturation genome editing with functional selection, mRNA dosage measurement, and isogenic cell line comparisons provide comprehensive mechanistic variant map\",\n      \"pmids\": [\"38969834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A small molecule binds the HIF1α-binding pocket on pVHL and functions as a molecular glue degrader, recruiting the neosubstrate cysteine dioxygenase 1 (CDO1) into the VHL–Cullin–RING E3 ligase complex for selective ubiquitin-dependent degradation; X-ray crystal structure of the ternary VHL–CDO1–degrader complex was solved.\",\n      \"method\": \"Protein array screening; mutagenesis; protein–protein docking + molecular dynamics; X-ray crystallography of ternary complex; cellular degradation assays\",\n      \"journal\": \"Nature Chemical Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — X-ray crystal structure of ternary complex, mutagenesis validation, and cellular degradation assay in one study\",\n      \"pmids\": [\"40555806\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"pVHL is the substrate-recognition subunit of a Cullin2–RING E3 ubiquitin ligase complex (CRL2VHL) that binds oxygen-dependently prolyl-hydroxylated HIFα subunits (and additional substrates including RAPTOR, Beclin1-Pro54-OH, TBK1-Pro48-OH, STING, and CDO1) to direct their K48-linked ubiquitination and proteasomal degradation; pVHL's interaction with HIFα can be blocked by lactylation of HIF-1α, by competing proteins (ID2, iASPP, DJ-1, RSUME), or by competitor E2s (UBE2S-mediated K11 ubiquitination of VHL itself), while pVHL also performs HIF-independent functions including stabilizing the mitotic spindle and Mad2 to ensure chromosomal fidelity, facilitating DNA double-strand break repair via SOCS1-mediated K63-ubiquitylation-driven nuclear redistribution, regulating CHCHD4-dependent mitochondrial function, and suppressing autophagy through direct binding to hydroxylated Beclin1.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"pVHL is the oxygen-sensitive substrate-recognition subunit of a Cullin2–Elongin B/C–RING E3 ubiquitin ligase that couples oxygen and metabolic status to targeted protein degradation [#0, #8]. Its canonical role is to bind HIFα only when a conserved proline is hydroxylated in an O2- and Fe2+-dependent manner, directing HIFα for proteasomal destruction; loss of this recognition drives constitutive HIF activity that remodels enhancer landscapes via HIF2α–HIF1β/p300 recruitment, suppresses E-cadherin, and induces a HEF1/Aurora kinase A axis promoting cilium loss [#0, #14, #4, #5]. Substrate scope extends beyond HIFα to additional proline-hydroxylated and other targets, including TBK1-Pro48-OH (restraining p62/SQSTM1 phosphorylation), Beclin1-Pro54-OH (whose binding blocks VPS34–ATG14L assembly to suppress autophagy initiation), RAPTOR (inhibiting mTORC1, conserved in C. elegans), and STING [#16, #19, #17, #20]. HIFα recognition is governed by an extensive regulatory layer: deubiquitination by VDU2, competing binders that occlude the substrate interface (ID2 displacing Cullin2, iASPP binding the β domain, DJ-1, RSUME), and HIF-1α lactylation that sterically blocks VHL contact [#2, #10, #23, #9, #12, #21]. pVHL abundance and localization are themselves controlled by post-translational modification—SUMOylation at K171 stabilizes and nuclearizes it while ubiquitylation at K171/K196 (including K11 linkages added by UBE2S and degradation driven by Daam2 or viral BC-box proteins) destabilizes it [#7, #22, #13, #8]. pVHL also performs HIF-independent functions: it localizes to the mitotic spindle to maintain spindle orientation, Mad2-dependent checkpoint fidelity, and chromosomal stability [#1, #26]; undergoes SOCS1-driven K63-ubiquitylation and nuclear redistribution to support homologous recombination repair [#6]; and elevates CHCHD4 and respiratory chain subunits to sustain mitochondrial respiration [#15]. In renal epithelium, VHL loss causes replication stress whose rescue by concomitant PBRM1 loss yields fully penetrant clear-cell renal carcinoma, and saturation editing of the coding sequence has resolved pathogenic alleles—some acting through mRNA dosage rather than protein dysfunction [#25, #27]. The HIFα-binding pocket is structurally tractable and exploitable for molecular-glue degraders that recruit neosubstrates such as CDO1 [#28].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established how pVHL achieves oxygen-sensitive substrate selection, answering how cells couple O2 availability to HIFα degradation.\",\n      \"evidence\": \"Peptide-binding and ubiquitination assays comparing hydroxylated vs. non-hydroxylated HIF peptides\",\n      \"pmids\": [\"11292862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not enumerate non-HIF substrates\", \"Structural basis of the ligase assembly not resolved here\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Revealed a HIF-independent role for pVHL in mitosis, addressing how VHL loss promotes chromosomal instability beyond hypoxia signaling.\",\n      \"evidence\": \"Spindle immunofluorescence, WT vs. disease-mutant rescue, and Mad2 epistasis in mammalian cells\",\n      \"pmids\": [\"19620968\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of spindle/microtubule stabilization by pVHL undefined\", \"How Mad2 levels are controlled by pVHL not established\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Confirmed in vivo that VHL maintains spindle orientation and checkpoint fidelity and that its loss seeds renal carcinoma precursors, extending the in vitro mitotic findings to tissue.\",\n      \"evidence\": \"Conditional Vhl-knockout mice with ischemic injury, spindle/FISH and histopathology readouts\",\n      \"pmids\": [\"24362914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal link between aneuploidy and tumor initiation not isolated\", \"Does not define the molecular spindle substrate\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined a regulated nuclear function of VHL in DNA repair, showing how DNA breaks redirect VHL to support homologous recombination.\",\n      \"evidence\": \"SOCS1-mediated K63-ubiquitylation, nuclear fractionation, and HR repair assays\",\n      \"pmids\": [\"23455319\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Nuclear substrate(s) of redistributed VHL unidentified\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed VHL loss imposes replication stress that requires a second hit to permit tumor growth, explaining the genetic cooperation underlying ccRCC.\",\n      \"evidence\": \"γH2AX/replication-stress assays and combined Vhl/Pbrm1 conditional mouse knockouts\",\n      \"pmids\": [\"29229903\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking VHL loss to replication stress not fully resolved\", \"Whether stress is HIF-dependent unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Connected VHL loss to epithelial dedifferentiation by demonstrating HIF-mediated E-cadherin suppression.\",\n      \"evidence\": \"VHL re-expression in RCC lines with HIF epistasis and E-cadherin readouts\",\n      \"pmids\": [\"16585181\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct HIF target mediating repression not pinned down\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified deubiquitination as a counter-regulatory mechanism opposing pVHL, showing HIF-1α stability is set by a ubiquitination/deubiquitination balance.\",\n      \"evidence\": \"VDU2–HIF-1α Co-IP, in vivo deubiquitination, and VEGF reporter assays\",\n      \"pmids\": [\"15776016\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No reconstitution of the opposing enzymatic cycle\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established post-translational control of pVHL itself, showing SUMOylation vs. ubiquitylation at K171/K196 dictate VHL stability and localization.\",\n      \"evidence\": \"SUMO/ubiquitin fusion constructs, fractionation, and HIFα reporter assays\",\n      \"pmids\": [\"20844582\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological triggers of K171 SUMOylation unclear\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined how VHL loss drives cilium loss and motility through a HIF-induced Aurora A/HEF1 axis.\",\n      \"evidence\": \"Knockdown/overexpression in VHL-defective cells with ciliation and motility assays\",\n      \"pmids\": [\"20864688\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative HIF-1 vs HIF-2 contribution not separated\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Distinguished folding instability from catalytic loss for missense pVHL, showing chaperone-targeting drugs can restore mutant function.\",\n      \"evidence\": \"In vitro E3 ligase assays, chaperone-interaction studies, and HDAC-inhibitor rescue with xenografts\",\n      \"pmids\": [\"23318261\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generality across the missense mutant spectrum untested\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed viral BC-box proteins hijack the Elongin B/C interface to degrade VHL, defining a competition-based route to HIF stabilization.\",\n      \"evidence\": \"Co-IP, proteasome rescue, and BC-box domain mapping with HIF reporters\",\n      \"pmids\": [\"24145437\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous BC-box competitors not comprehensively mapped\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified DJ-1 as a binder that blocks the HIF–VHL interaction, linking VHL regulation to oxidative-stress neuroprotection.\",\n      \"evidence\": \"DJ-1–VHL Co-IP, HIF-1α ubiquitination/stability, and neuroprotection assays\",\n      \"pmids\": [\"24899725\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Binding interface on VHL not mapped\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established RSUME as a SUMO-dependent inhibitor of ECV complex assembly required for type-2 mutant loss-of-function.\",\n      \"evidence\": \"Co-IP, SUMOylation and ECV assembly assays, HIF ubiquitination, and xenografts\",\n      \"pmids\": [\"25500545\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which SUMO sites mediate the effect not fully defined\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined a phospho-regulated competitor (ID2) that displaces Cullin2 from VHL, showing kinase signaling tunes HIF2α degradation.\",\n      \"evidence\": \"ID2–VHL Co-IP, HIF2α ubiquitination, DYRK1A/B kinase assays, Thr27 mutagenesis, and glioma xenografts\",\n      \"pmids\": [\"26735018\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity for HIF2α over HIF1α not fully explained\", \"In vivo prevalence of ID2 competition across tumors unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed VHL loss reprograms the enhancer landscape via stabilized HIF2α–HIF1β and p300 recruitment, linking VHL to chromatin-level gene deregulation in ccRCC.\",\n      \"evidence\": \"ChIP-seq for histone marks, HIF2α, and p300 across primary tumors and cell lines\",\n      \"pmids\": [\"28893800\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal contribution of individual enhancers to tumorigenesis untested\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified Daam2 as a non-mutational driver of VHL degradation in glioma.\",\n      \"evidence\": \"Daam2–VHL Co-IP, ubiquitination, stability, and tumor growth assays\",\n      \"pmids\": [\"29053101\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase mediating Daam2-driven VHL ubiquitination not defined here\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined a HIF-independent role for pVHL in sustaining mitochondrial respiration via CHCHD4.\",\n      \"evidence\": \"VHL re-expression and HIF-2α knockdown with OCR and respiratory-subunit measurements\",\n      \"pmids\": [\"30338240\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which pVHL elevates CHCHD4 unresolved\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended VHL substrate logic to TBK1 via Pro48 hydroxylation, showing VHL loss hyperactivates TBK1 to stabilize p62 and drive proliferation.\",\n      \"evidence\": \"VHL–TBK1 Co-IP, hydroxylation/phosphorylation assays, and xenografts\",\n      \"pmids\": [\"31810986\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether TBK1 is ubiquitinated/degraded by VHL or only sequestered unclear\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed VHL in a developmental Daam2–VHL–Nedd4 axis controlling oligodendrocyte differentiation and myelination, with Nedd4 stabilizing VHL via K63 ubiquitination.\",\n      \"evidence\": \"Proteomics, Co-IP, conditional KO mice, K63 ubiquitination assays, and human MS lesion analysis\",\n      \"pmids\": [\"32792353\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream VHL substrate in oligodendrocytes not defined\", \"How the axis integrates with HIF signaling unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified RAPTOR as a VHL substrate, linking VHL to mTORC1 restraint with cross-species conservation.\",\n      \"evidence\": \"VHL–RAPTOR Co-IP, ubiquitination, mTORC1 activity assays, and C. elegans vhl-1 genetics\",\n      \"pmids\": [\"34290272\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether RAPTOR recognition requires hydroxylation not established\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed a negative feedback in which VHL–HIFα interface inhibitors paradoxically stabilize VHL protein.\",\n      \"evidence\": \"Quantitative MS proteomics and cycloheximide-chase stability assays after VH298 treatment\",\n      \"pmids\": [\"34174286\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism coupling substrate engagement to VHL turnover not resolved\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established STING as a VHL E3 substrate and demonstrated VHL-recruiting PROTAC degradation depending on STING trafficking.\",\n      \"evidence\": \"PROTAC degradation, ER-retention mutagenesis, Co-IP, and innate immune signaling assays\",\n      \"pmids\": [\"37183204\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether STING recognition is hydroxylation-dependent not defined\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified iASPP as a β-domain competitor that blocks HIF-1α degradation even in VHL-wild-type tumors.\",\n      \"evidence\": \"iASPP–VHL Co-IP, β-domain mapping, ubiquitination competition, and xenografts\",\n      \"pmids\": [\"35169254\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Regulation of iASPP–VHL binding in normoxia unclear\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined the autophagy-suppressing function of VHL through binding hydroxylated Beclin1 to block VPS34–ATG14L assembly.\",\n      \"evidence\": \"VHL–Beclin1 Co-IP, PHD1 hydroxylation, Pro54 mutagenesis, VPS34 pull-down, and autophagy flux assays\",\n      \"pmids\": [\"38360997\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Beclin1 is also ubiquitinated/degraded vs. only sequestered not fully addressed\", \"In vivo autophagy consequences in VHL-disease tissue not characterized\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed metabolite-driven lactylation of HIF-1α sterically blocks VHL binding without affecting prolyl hydroxylation, defining a metabolism-coupled escape from degradation.\",\n      \"evidence\": \"MS lactylation mapping, mutagenesis, K48 ubiquitination, VHL Co-IP, and ChIP\",\n      \"pmids\": [\"40760493\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enzymes catalyzing/removing HIF-1α lactylation not defined here\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed UBE2S adds K11-linked polyubiquitin to VHL K171/K196 independently of an E3, degrading VHL and indirectly stabilizing HIF-1α in HCC.\",\n      \"evidence\": \"Co-IP, K11-specific ubiquitination, VHL stability, and glycolysis assays\",\n      \"pmids\": [\"38915206\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How an E2 acts E3-independently on VHL mechanistically unresolved\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Built a comprehensive functional variant map distinguishing ccRCC- from pheochromocytoma-associated alleles and revealing mRNA-dosage mechanisms of pathogenicity.\",\n      \"evidence\": \"Saturation genome editing of 2,268 variants with functional selection and mRNA quantification\",\n      \"pmids\": [\"38969834\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic basis of phenotype-specific allele effects not fully explained\", \"Functional scores derived in selected cell systems\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrated the HIF1α-binding pocket on pVHL can be redirected by a molecular-glue degrader to recruit and degrade neosubstrates such as CDO1, providing a structural basis for VHL-based degraders.\",\n      \"evidence\": \"Protein array screening, docking/MD, X-ray crystallography of the ternary VHL–CDO1–degrader complex, and cellular degradation\",\n      \"pmids\": [\"40555806\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalizability to other neosubstrates not established\", \"In vivo efficacy not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the many competing substrates and regulators of pVHL are prioritized in vivo and whether non-HIF substrates require proline hydroxylation as a universal recognition rule.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model integrating spindle, repair, mitochondrial, and ligase functions\", \"Substrate recognition determinants beyond hydroxyproline not generalized\", \"Tissue-specific substrate hierarchy unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [0, 16, 17, 19, 20]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 17, 20]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [19, 17]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [1, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 7]},\n      {\"term_id\": \"GO:0005819\", \"supporting_discovery_ids\": [1, 26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 8, 16, 17, 19, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [25, 27]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [14, 4]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [1, 26]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [6, 25]}\n    ],\n    \"complexes\": [\"CRL2VHL (pVHL–Elongin B/C–Cullin2–RING E3 ligase)\"],\n    \"partners\": [\"HIF1A\", \"ELOB\", \"ELOC\", \"CUL2\", \"ID2\", \"DAAM2\", \"BECN1\", \"TBK1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}